Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy
Authors:
- Min LiMLMin Li
- Na ZhangNZNa Zhang
Open Access
- 1 June 2012
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 7, 3281-3294
Abstract
The purpose of this study was to develop two novel drug delivery systems based on biodegradable docetaxel-lipid-based-nanosuspensions. The first one was poly(ethylene glycol)-modified docetaxel-lipid-based-nanosuspensions (pLNS). It was developed to increase the cycle time of the drug within the body and enhance the accumulation of the drug at the tumor site. The second one was targeted docetaxel-lipid-based-nanosuspensions (tLNS) using folate as the target ligand. The tLNS could target the tumor cells that overexpressed folate receptor (FR). The morphology, particle size, and zeta potential of pLNS and tLNS were characterized, respectively. The in vitro cytotoxicity evaluation of Duopafei®, pLNS, and tLNS were performed in human hepatocellular liver carcinoma HepG2 (FR-) and B16 (FR+) cells, respectively. The in vivo antitumor efficacy and pharmacokinetics, as well as the drug tissue distribution, were evaluated in Kunming mice bearing B16 cells. The particle size of pLNS was 204.2 ± 6.18 nm and tLNS had a mean particle size of 220.6 ± 9.54 nm. Cytotoxicity of tLNS against B16 (FR+) cell lines was superior to pLNS (P < 0.05), while there was no significant difference in the half maximum inhibitory concentration values for HepG2 (FR-) cells between pLNS and tLNS. The results of the in vivo antitumor efficacy evaluation showed that tLNS exhibited higher antitumor efficacy by reducing tumor volume (P < 0.01) compared with Duopafei and pLNS, respectively. The results of the in vivo biodistribution study indicate that the better antitumor efficacy of tLNS was attributed to the increased accumulation of the drug in the tumor.Keywords
This publication has 43 references indexed in Scilit:
- Folate-functionalized nanoparticles for controlled 5-Fluorouracil deliveryJournal of Colloid and Interface Science, 2011
- Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactorsInternational Journal of Pharmaceutics, 2009
- l-Histidine-based pH-sensitive anticancer drug carrier micelle: Reconstitution and brief evaluation of its systemic toxicityInternational Journal of Pharmaceutics, 2008
- Application of Nanotechnology in Cancer Therapy and ImagingCA: A Cancer Journal for Clinicians, 2008
- Cell-Specific Delivery of Polymeric Nanoparticles to Carbohydrate-Tagging CellsBiomacromolecules, 2007
- Receptor-mediated gene delivery by folate-PEG-baculovirus in vitroJournal of Biotechnology, 2007
- Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug deliveryMolecular Cancer Therapeutics, 2006
- Effect of Polyethylene Glycol Linker Chain Length of Folate-Linked Microemulsions Loading Aclacinomycin A on Targeting Ability and Antitumor Effect In vitro and In vivoClinical Cancer Research, 2005
- Folate-mediated delivery of macromolecular anticancer therapeutic agentsAdvanced Drug Delivery Reviews, 2002
- HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell lineJournal of Controlled Release, 1998